NYSE:DHRLife Sciences
Danaher (DHR) Could Be 16% Undervalued Following Q2 Results And Fresh Guidance
Danaher (DHR) is back in focus after its second quarter report paired higher sales and net income with fresh third quarter revenue guidance, giving investors an updated view on the company’s near term outlook.
See our latest analysis for Danaher.
Danaher’s share price has been under pressure this year, with a year to date share price return down 16.88%, while the 1 year total shareholder return is down 6.12%. This suggests momentum has softened even as recent earnings and buyback activity...